Glycoprotein / GP (virus)

Glycoprotein / GP (virus) 분자 정보

영어 이름Envelope glycoprotein시판 약물 수2
임상 약물 수2표적 별명GP1,2,GP,Envelope glycoprotein
최고 연구 개발 단계Approved
영어 이름Envelope glycoprotein
표적 별명GP1,2,GP,Envelope glycoprotein
시판 약물 수2
임상 약물 수2
최고 연구 개발 단계Approved

제품 문의

Glycoprotein / GP (virus)분자 배경

EBOV encodes seven structural proteins: nucleoprotein (NP), polymerase cofactor (VP35), (VP40), GP, transcription activator (VP30), VP24, and RNA polymerase (L). GP protein contains 160-kDa envelope-attached glycoprotein (GP) and a 110 kDa secreted glycoprotein (sGP). GP is a class I fusion protein which assembles as trimers on viral surface and plays an important role in virus entry and attachment. Mature GP is a disulfide-linked heterodimer formed by two subunits, GP1 and GP2, which are generated from the proteolytical process of GP precursor (pre-GP) by cellular furin during virus assembly . GP1 is responsible for binding to the receptor(s) on target cells. Interacts with CD209/DC-SIGN and CLEC4M/DC-SIGNR which act as cofactors for virus entry into the host cell. GP2 acts as a class I viral fusion protein. GP1,2 mediates endothelial cell activation and decreases endothelial barrier function. sGP seems to possess an anti-inflammatory activity as it can reverse the barrier-decreasing effects of TNF alpha.

Glycoprotein / GP (virus)분자 별명

GP,Envelope glycoprotein,GP(1,2)

임상 약물 정보

영어 이름연구 코드연구 개발 단계회사적응증임상 시험
Porgaviximab/Larcaviximab/Cosfroviximabc2G4-N; c4G7; c13C6Phase 3 ClinicalMapp Biopharmaceutical, Public Health Agency Of Canada'S National Microbiology LaboratoryHemorrhagic Fever, Ebola
상세
MIL-77MIL-77Phase 1 ClinicalBeijing Mabworks Biotech Co Ltd, Zhejiang Hisun Pharmaceutical Co Ltd, Institute Of Basic Medicine Academy Of Military Medical SciencesHemorrhagic Fever, Ebola
상세

시판 약물 정보

영어 이름연구 코드연구 개발 단계회사가장 빠른 브랜드 이름가장 빠른 승인 국가가장 빠른 적응증가장 빠른 승인 회사가장 빠른 승인 날짜적응증임상 시험
AnsuvimabVRC-EBOMAB092-00-AB; MAb114; MAb-114ApprovedNational Institute Of Allergy And Infectious Diseases (Niaid), National Institute of Health, IslamabadEbangaUnited StatesHemorrhagic Fever, EbolaRidgeback Biotherapeutics Lp2020-12-21Hemorrhagic Fever, Ebola
상세
Atoltivimab/Maftivimab/OdesivimabREGN3470-3471-3479; REGN-EB3ApprovedRegeneron Pharmaceuticals IncInmazebUnited StatesHemorrhagic Fever, EbolaRegeneron Pharmaceuticals Inc2020-10-14Hemorrhagic Fever, Ebola
상세
  • 분자 정보
  • 제품 문의
  • 시판 약물 정보
  • 임상 약물 정보